BioPharma Dive - Latest News

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI and a widening definition of what constitutes women’s health could spur a rebound, some say.

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.